Literature DB >> 34817799

Intranasal Exposure to Low-Dose Rotenone Induced Alpha-Synuclein Accumulation and Parkinson's Like Symptoms Without Loss of Dopaminergic Neurons.

Jaswinder Kaur1, Siddhi Rakshe1, Monika Sharma1, Nishant Sharma1, Dignesh Khunt2, Amit Khairnar3.   

Abstract

Epidemiologically Parkinson's disease (PD) is associated with chronic ingestion or inhalation of environmental toxins leading to the development of motor symptoms. Though neurotoxin-based animal models played a major role in understanding diverse pathogenesis, they failed to identify the risk assessment due to uncommon route of toxin exposure. Towards this, the available neurotoxin-based intranasal (i.n.) PD models targeting olfactory bulb (OB) have demonstrated the dopaminergic (DAergic) neurodegeneration in both OB and substantia nigra (SN). Despite that, the studies detecting the alpha-synuclein (α-syn) accumulation in OB and its progression to other brain regions due to inhalation of environmental toxins are still lacking. Herein, we developed oil in water microemulsion of rotenone administered intranasally to the mice at a dose which is not detectable in blood, brain, and olfactory bulb by LCMS method. Our data reveals that 9 weeks of rotenone exposure did not induce olfactory and motor dysfunction. Conversely, after 16 weeks of washout period, rotenone treated mice showed both olfactory and motor impairment, along with α-syn accumulation in the OB and striatum without glial cell activation and loss of dopaminergic neurons. The results depict the progressive nature of the developed model and highlight the role of α-syn in PD like pathology or symptoms. Together, our findings suggest the adverse consequences of early exposure to the environmental toxins on the olfactory system for a shorter period with relevance to the development of synucleinopathy or Parkinson's disease in its later stage.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alpha-synuclein; Dopaminergic neurodegeneration; Intranasal; Olfactory bulb; Parkinson’s disease; Phosphorylated alpha-synuclein; Rotenone

Mesh:

Substances:

Year:  2021        PMID: 34817799     DOI: 10.1007/s12640-021-00436-9

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  42 in total

1.  Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.

Authors:  M Alam; W J Schmidt
Journal:  Behav Brain Res       Date:  2002-10-17       Impact factor: 3.332

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson's disease.

Authors:  Ariana Q Farrand; Ryan S Verner; Ryan M McGuire; Kristi L Helke; Vanessa K Hinson; Heather A Boger
Journal:  Brain Stimul       Date:  2020-07-03       Impact factor: 8.955

4.  Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.

Authors:  S M Fleming; J Salcedo; C B Hutson; E Rockenstein; E Masliah; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2006-08-23       Impact factor: 3.590

5.  Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging.

Authors:  F Cicchetti; A L Brownell; K Williams; Y I Chen; E Livni; O Isacson
Journal:  Eur J Neurosci       Date:  2002-03       Impact factor: 3.386

Review 6.  Toxin-induced models of Parkinson's disease.

Authors:  Jordi Bové; Delphine Prou; Céline Perier; Serge Przedborski
Journal:  NeuroRx       Date:  2005-07

Review 7.  A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.

Authors:  Marie-Francoise Chesselet; Franziska Richter; Chunni Zhu; Iddo Magen; Melanie B Watson; Sudhakar R Subramaniam
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 8.  Parkinson's disease and parkinsonism: neuropathology.

Authors:  Dennis W Dickson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

9.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.

Authors:  Paula Desplats; He-Jin Lee; Eun-Jin Bae; Christina Patrick; Edward Rockenstein; Leslie Crews; Brian Spencer; Eliezer Masliah; Seung-Jae Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

Review 10.  Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

View more
  3 in total

1.  Taste Impairments in a Parkinson's Disease Model Featuring Intranasal Rotenone Administration in Mice.

Authors:  Dong Xu Yin; Hiroki Toyoda; Kazunori Nozaki; Keitaro Satoh; Ayano Katagiri; Kazunori Adachi; Takafumi Kato; Hajime Sato
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

2.  AMPK-dependent autophagy activation and alpha-Synuclein clearance: a putative mechanism behind alpha-mangostin's neuroprotection in a rotenone-induced mouse model of Parkinson's disease.

Authors:  Pathik Parekh; Nishant Sharma; Monika Sharma; Anagha Gadepalli; Adil Ali Sayyed; Sayan Chatterjee; Abhijeet Kate; Amit Khairnar
Journal:  Metab Brain Dis       Date:  2022-09-30       Impact factor: 3.655

3.  Chlorogenic Acid: a Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson's Disease by GLP-1 Secretion.

Authors:  Nishant Sharma; Ritu Soni; Monika Sharma; Sayan Chatterjee; Nidhi Parihar; Mohd Mukarram; Ruhi Kale; Adil Ali Sayyed; Santosh Kumar Behera; Amit Khairnar
Journal:  Mol Neurobiol       Date:  2022-09-01       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.